Our TΞAM

FOUNDERS

Terence Beghyn

Founder & CEO

Native of Région Hauts-de-France, i am a pharmacist and holds a Ph.D. in medicinal chemistry. In 2007, I was appointed lecturer at the Faculty of Pharmacy (University of Lille). Passionate about all drug discovery technologies, I participated in the establishment of several high technology platforms and in the design of the chemical library screening platform of Institut Pasteur de Lille. My research has focused on the discovery of novel pharmacological activities of drugs already on the market, work funded to the tune of € 550,000 by two ANR Emergence programs. I am the author of 10 peer-reviewed scientific articles and inventors on two patents. Envious of enterprise, Benoit and I launched the pharmaRedux project in 2010. Incubated by Eurasanté, the project was awarded at OSEO-MESR Emergence in 2011 and Creation-Development in 2012 subsidizing it to the tune of € 275,000. In 2014, we create APTEEUS, and I took over as CEO.

Benoit Deprez

Founder & Strategic advisor

Benoit studied Industrial Pharmacy Lille from 1985 to 1991 and received his PhD in combinatorial chemistry. With Andre Tartar he created the automated parallel synthesis laboratory at the Institut Pasteur de Lille, becoming later the department of drug discovery of Cerep (30 employees). To finance its development, Cerep goes public in 1998, having signed a major collaboration agreement with Sanofi. In late 1999, Benoit and part of his team join the young company Devgen to launch drug discovery activities. Benoit Deprez has managed several multi-annual collaborations with pharmaceutical companies and biotechs. In 2006, he founded a drug discovery lab at INSERM. The laboratory has run into several collaborations with industries and licensed several patents. Benoit was a member of the Strategic Committee of Inserm-transfer for 5 years. He is a member of the National Academy of Pharmacy and advisor to several venture funds. He is author of 80 international publications and 12 patent families. In March 2014, he obtained an MBA from EDHEC.

Operational team

Camille Moreau

engineer

In 2013, Camille graduated from the Ecole Nationale Supérieure de Chimie de Lille (ENSCL), in Chemical Engineering.  During the last semester of her training, she studied specifically analytical chemistry and biochemistry at the University of Edinburgh. Camille joined APTEEUS in 2014, and now develops assays for screening and supervises individualized screening of patients.

Loïc Belloy

engineer

Engineer, graduated from a master’s degree in cellular and molecular engineering at the University of Lille 1 in 2010, I worked in academic laboratories and a biopharmaceutical company in Lille.
Working on different themes has enabled me to acquire various knowledge and skills in Biology that I am happy to bring today to APTEEUS by continuing to learn from the whole team.

Betty Dubois

engineer

I graduated from Master’s degree in Biotechnology specialized in cellular and molecular engineering at the University of Lille. During my internships, I worked on different projects where I consolidated my knowledge in Biotechnology.

Working at Apteeus like an engineer is a great opportunity given the expertise that the company can bring me. In the team, I participate to the project progress by implementing molecular and cellular techniques while being responsible for the management of the cellular culture.

Thibaut VAUSSELIN

PHD

Holder of a doctorate in molecular and cellular biology from the University of Lille, focusing on the study of inhibitors of the hepatitis C virus (HCV). I then specialized in high-throughput screening during a first post-doctorate of 4.5 years in the microbiology department of Mount Sinai in New York, USA, before returning to the Center of Infection and Immunity de Lille (CIIL) as part of a second postdoc.

The various screening projects allowed me to acquire a solid experience in the identification of host factors involved in viral cycle (by RNA-interference method on HCV and Influenza virus) and of antiviral molecules (aimed at inhibiting Ebola virus polymerase).

The different study models and methods used also allowed me to better understand and master the constraints related to the screening technique according to their context, and to acquire additional skills in fields relating to bioinformatics, robotics or statistical analysis, giving me some ease in establishing and analyzing high-throughput studies.

I put my expertise at the service of the consortium behind the discovery of the drug candidate TEE001 currently in development in Covid19 by Apteeus and Institut Pasteur de Lille. It was in this context that I joined the Apteeus team.